Book helps kids prepare for eye surgery
August 15th 2006As a pediatric ophthalmologist, Mark Silverberg, MD, relies on special tactics and tools to make his young patients feel at ease. Dr. Silverberg is pleased to have a new book to share with kids and their families that tells the story of eye surgery from a child's perspective, in simple terms with illustrative photographs.
Transitions Online Marketing materials available in Spanish
August 15th 2006Pinellas Park, FL-Transitions Optical Inc. continues to spread the word about the importance of protecting eyes from ultraviolet (UV) radiation with an expanded consumer initiative geared toward the rising Hispanic-origin population in the United States.
Should CTRs be implanted in every patient with PXE?
August 15th 2006Cataract surgery in the presence of pseudoexfoliation of the lens (PXE) presents surgeons with many challenges. In addition to a higher incidence of glaucoma, these patients have loss of zonular integrity, occasionally associated with lens subluxation and pupils that dilate poorly.
Initial treatment for lid wiper epitheliopathy effective
August 15th 2006Fort Lauderdale, FL-Both a corticosteroid (loteprednol etabonate ophthalmic suspension, Lotemax, Bausch & Lomb) and an oil-in-water emulsion (Soothe Emollient Eye Drops, Alimera Sciences) effectively minimized or eliminated lid wiper epitheliopathy findings and symptoms during an initial treatment period of 5 to 10 weeks. The oil-in-water emulsion regimen without corticosteroids controlled lid wiper epitheliopathy findings and symptoms in an extended 1-year study.
Mast cell stabilizer offers daily relief for allergy sufferers
August 15th 2006Boston-With the advances in anti-allergy medications that have taken place in the recent past, nedocromil sodium ophthalmic solution 2% (Alocril Ophthalmic Solution, Allergan) fills a niche for those patients who do not find relief with the newest combination antihistamine/mast cell stabilizers, Mich?l Raizman, MD, told Ophthalmology Times.
Pediatric ocular allergy can be alleviated
August 15th 2006Chicago-High allergen counts this season combined with increased parental awareness about the potential functional impact of allergic conjunctivitis are leading to an increase in the number of pediatric patients being seen for control of ocular allergy.
Dry eye symptoms return with cyclosporine cessation
August 15th 2006San Francisco-Discontinuing the use of cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan), the only FDA-approved drug to treat dry eye, may result in recurrence of the signs and symptoms of keratoconjunctivitis sicca (KCS), and reinstitution of the drug is needed to reverse those signs and symptoms, John Sheppard, MD, reported at the annual meeting of the American Society of Cataract and Refractive Surgery.
Topical allergy agents keep ocular surface safe
August 15th 2006Commonly used systemic antihistamines taken for seasonal allergies can cause ocular surface drying that in turn aggravates ocular allergy symptoms. Antihistamine drops specifically formulated for ocular allergies, in contrast, do not appear to decrease tear volume or tear flow or cause ocular surface damage, according to several investigators who have studied ocular drying. However, in a separate mouse study, topical ocular allergy medications themselves may have different effects on tear volume or tear flow.
Effects of dry eye therapy continue after treatment stopped
August 15th 2006San Francisco-The effects of Systane lubricant eye drops (Alcon Laboratories) persist for about 3.5 weeks after the treatment is stopped, according to James McCulley, MD. At that time, the signs and symptoms of dry eye increase significantly compared with the baseline values when the patients were still being treated with the eye drops.
Flaxseed oil helps to prevent dry eye after LASIK
August 15th 2006San Francisco-Flaxseed oil seems to be as effective as doxycycline in preventing the development of dry eye after LASIK. Colin C.K. Chan, MD, speculated that the reason may be due to its anti-inflammatory and lipid-modifying properties. He presented his ideas at the annual meeting of the American Society of Cataract and Refractive Surgery.
Deeper understanding of dry eye surfaces
August 15th 2006Houston-While dry eye disease has been known to cause ocular surface damage, researchers did not understand how this happened until recently. For a long time, ocular surface damage was attributed to the drying effect of the disease, but the use of artificial tears did not improve the situation. Researchers now know that inflammation is a key component of dry eye disease leading to ocular surface problems, reported Stephen C. Pflugfelder, MD.
Retina center teams up with high school student
August 15th 2006Fort Myers, FL-Last year Sabrina Prabakaran, a high school student at Canterbury School, met with the Retina Health Center team to discuss a research project to investigate further the value of bevacizumab (Avastin) in the treatment of wet age-related macular degeneration (AMD). The drug is currently approved for the treatment of colon cancer. The research project is now complete, and the findings show that nearly half of patients with AMD and taking bevacizumab showed improvement in vision.
Lumenis' Selecta II approved in China
August 15th 2006Yokneam, Isr?l-China's regulatory agency for medical devices approved Lumenis to market Selecta II Selective Laser Trabeculoplasty (SLT) technology for treatment of glaucoma. The device reduces IOP associated with glaucoma. The key aspect of Selecta II is that medications are not required postoperatively.
ISTA recives rights to investigational drugs
August 15th 2006Irvine, CA-Senju Pharmaceuticals will transfer exclusive North American rights of two investigational drugs-iganidipine, a calcium-channel blocker, and a new formulation of latanoprost, a prostaglandin analogue-to ISTA Pharmaceuticals. Both investigational formulations may treat glaucoma or other ophthalmic applications.